

## Activity Survey 2014

### Patient and Transplant Numbers

	Participating countries: 47		
	Allogeneic	Autologous	Total
Teams : 656			
<b>1st Allo /auto HSCT</b>	<b>15765</b>	<b>20704</b>	<b>36469</b>
Retransplant	1105	1594	2699
Additional transplant	76	1585	1661
<b>Total</b>	<b>16946</b>	<b>23883</b>	<b>40829</b>

### Main Indications 1st HSCT

	Allogeneic	Autologous	Total
Leukaemia	11348	505	11853
Lymphoid neoplasia	2292	18510	20802
Bone marrow failure	833	4	837
Solid tumour	44	1414	1458
Non-malignant dis. (excl. BMF)	1109	257	1366
Other	139	14	153

### Leukaemia

	Allogeneic	Autologous	Total
AML 1 <sup>st</sup> . CR	3670	325	3995
not 1 <sup>st</sup> . CR	2064	58	2122
ALL 1 <sup>st</sup> . CR	1537	81	1618
not 1 <sup>st</sup> . CR	918	8	926
CML 1 <sup>st</sup> . cP	198	1	199
not 1 <sup>st</sup> . cP	215	2	217
MDS or MD/MPN, MPN	2393	11	2404
CLL	353	19	372

### Lymphoid neoplasia

	Allogeneic	Autologous	Total
Plasma cell disorders	580	10421	11001
Hodgkin lymphoma	477	2028	2505
Non-Hodgkin lymphoma	1235	6061	7296

### Solid tumour

	Allogeneic	Autologous	Total
Neuroblastoma	16	467	483
Soft tissue sarcoma	9	19	28
Germ cell tumour	0	306	306
Breast cancer	5	31	36
Ewing	7	199	206
Other solid tumour	7	392	399

### Non-malignant disorder

	Allogeneic	Autologous	Total
Bone marrow failure - SAA	617	3	620
Bone marrow failure - other	216	1	217
Hemoglobinopathy- thalassemia	337	1	338
Hemoglobinopathy - sickle	105	2	107
Primary immune deficiency	499	5	504
Inherited disorder of metabolism	155	9	164
Auto immune disorder	13	240	253
Others	139	14	153

### Paediatric patients

Family			Unrelated			Autologous		
HLA-id/twin		non-id				BM +		
BM	PBPC	Cord	BM	PBPC	Cord	BM	PBPC	cord
905	289	34	186	313	2	859	441	250
						1121		
						3279		


### Additional information

Non myeloablative transplants	6871	No. patients with DLI	2649
Cellular therapies			
No. patients with MSC for GvHD treatment/prevention			450
No. patients with MSC for graft enhancement			27
No. patients with MSC unspecified			48

helen.baldomero@usb.ch


## HSCT in Europe 2014

### Main Indication by transplant type




### Numbers of HSCT and teams by donor type in Europe 1990 to 2014

#### Absolute numbers of HSCT




#### Number of teams by donor type




### Percentage increase in HSCT activity between the years 2004 and 2014 in countries reporting >100 HSCT in 2014


#### Increase in allogeneic HSCT



#### Increase in autologous HSCT



### No. allogeneic transplants 2014 per 10 million population



### No. autologous transplants 2014 per 10 million population

